Companies Directory

Biogaz services est spécialisé dans le montage, le suivi biologique, l’entretien et la maintenance d’unités de méthanisation. Nous intervenons sur des installations de toutes marques avec des technologies diverses de production de biogaz

Biogazelle offers expert laboratory services (some of which under ISO 17025 accreditation or GCLP compliancy) in the area of transcriptome and genomic analysis. To this purpose, various nucleic acid quantification methods such as RNA sequencing, quantitative PCR and digital PCR are being used, supported by unique software tools for data-analysis. State-of-the-art RNA sequencing workflows are optimized for quantification of coding and non-coding (small RNA and long non-coding RNA) genes in all type of clinically relevant samples, including FFPE tissue and body fluids, with minimal input requirements. Beyond gene expression level analysis, Biogazelle also performs RNA variant identification (e.g. mutations and fusion genes), and has established an RNA biomarker development program offering an end-to-end solution from RNA biomarker panel discovery to the development of a PCR-based molecular diagnostic test. Our proprietary RNA biomarker discovery platform covers the entire workflow from study design, data generation to identification of RNA biomarkers. Advanced data mining methods are applied to identify robust biomarker signatures that are further developed into a PCR-based biomarker assay (e.g. LDT, CE-IVD, CDx) Of note, Biogazelle also serves as a specialty lab in the field of clinical trials or in routine diagnostic settings. If you need a lab with internationally recognized and accredited expertise in RT-qPCR or digital PCR for running your clinical samples, for example using a test that we developed in a previous phase for you, Biogazelle can support you perfectly well.

Biogazelle offers expert laboratory services (some of which under ISO 17025 accreditation or GCLP compliancy) in the area of transcriptome and genomic analysis. To this purpose, various nucleic acid quantification methods such as RNA sequencing, quantitative PCR and digital PCR are being used, supported by unique software tools for data-analysis. State-of-the-art RNA sequencing workflows are optimized for quantification of coding and non-coding (small RNA and long non-coding RNA) genes in all type of clinically relevant samples, including FFPE tissue and body fluids, with minimal input requirements. Beyond gene expression level analysis, Biogazelle also performs RNA variant identification (e.g. mutations and fusion genes), and has established an RNA biomarker development program offering an end-to-end solution from RNA biomarker panel discovery to the development of a PCR-based molecular diagnostic test. Our proprietary RNA biomarker discovery platform covers the entire workflow from study design, data generation to identification of RNA biomarkers. Advanced data mining methods are applied to identify robust biomarker signatures that are further developed into a PCR-based biomarker assay (e.g. LDT, CE-IVD, CDx) Of note, Biogazelle also serves as a specialty lab in the field of clinical trials or in routine diagnostic settings. If you need a lab with internationally recognized and accredited expertise in RT-qPCR or digital PCR for running your clinical samples, for example using a test that we developed in a previous phase for you, Biogazelle can support you perfectly well.

BIOGENA – Your Partner in Health and Wellbeing BIOGENA commited itself to health and science. Our aim is to share our knowledgewith you so that we can establish a basis for a healthy lifestyle together. More knowledge With the largest scientific team in the industry and our BIOGENAAkademie, we create, grow and share knowledge. We keep up to date with the latest science, while at the same time tracking down ancient knowledge. We are supported in this by more than 9,000 partner doctors and therapists, top researchers and raw material manufacturers. More product quality Management and owners share their employees'​ passion for radically high quality and they personally guarantee this quality – for example, via quality controls for each individual batch, or our pure-substance principle: all micronutrient compounds are guaranteed to be pure – no food colourings, preservatives or processing aids. More responsibility We are an Austrian family business who take responsibility for our environment, our employees and our society. Our fundamental guiding principles are ecology and resource sustainability, with examples including: carbon neutrality, and the world’s first eco-bottle in this sector.

We are a biotechnology company, specialized in the development, production and commercialization of products for animal health.

Landfill tax free hazardous soil treatment and disposal without sacrificing compliance Following establishment of the first UK Soil Treatment Facility (STF) in 2005, Biogenie-Englobe, has grown to become the operator of the largest number of STFs in the UK. Through this network of treatment facilities, a joint venture with Biffa Waste Services, we are able to provide you with national coverage for sustainable, fully compliant and crucially, landfill tax free, off-site treatment of a wide range of hazardous wastes. We currently operate 4 STFs across the UK, 2 in the South East both close to the M25, one just north of Birmingham in the Midlands and one in Leeds. More new facilities and treatment technologies are planned in the next 12 - 18 months, follow us to keep up to date on all of the exciting new developments!

Biogenomics is a science-driven, vertically integrated pharmaceutical company specializing in treatments for diabetes and oncology. Backed by Oman Investment Authority and guided by a team of distinguished scientists, business leaders, and experts in molecular biology, microbiology, and protein engineering, Biogenomics has in a short span of time has developed a wide portfolio of biosimilars and biotech products. As an industry pioneer, Biogenomics became the first company in India to successfully launch a biosimilar of Insulin Aspart. With a robust pipeline, the company has several additional products awaiting approval. Committed to enhancing patient outcomes globally, Biogenomics has an active clinical development program focused on advancing chemical entities and biologics for the treatment of diabetes, cancer, and other critical therapeutic areas. As a young, fast-growing biopharmaceutical firm, Biogenomics is on a path to delivering excellence in healthcare. Our mission is to enrich lives by providing high-quality, affordable drugs, ensuring patient access to expensive specialty pharmaceuticals and biologic treatments. With two new additional manufacturing facilities coming up in India and Oman, Biogenomics is poised for significant global expansion. Beginning filings in 2025, the company plans to extend its reach into North America, Europe, and other key markets, further solidifying its international presence.

Bioglan AB is a contract development and manufacturing organization with more than thirty years of experience in research, development, manufacturing and marketing of pharmaceuticals. We develop, produce and market pharmaceuticals and medical devices. We also provide support for pharmaceutical, healthcare and life science companies in all aspects of development and manufacturing of semi-solid and liquid products. We collaborate with companies of all sizes, from the smallest start-up to the leading pharmaceutical companies. Our manufacturing authorization from the Swedish Medical Products Agency allows us to produce non-sterile semi-solid and liquid products, both at pilot scale for clinical trials or at full-scale to supply a large commercial market. We can even be your QP release site for other types of products. Our quality system fulfils the EU and FDA GMP (Good Manufacturing Practice) requirements as well as the ISO 13485 standard for Medical Devices. Bioglan is a reliable, efficient and flexible organization that delivers projects with the best quality at the right time in a cost-effective way. We are proud that we meet the quality requirements of the global markets.